Business & Finance
GenSight Biologics elects Laurence Rodriguez, Robert Schupp and Neil Dugdale as the country leads for France, Germany and the UK, respectively
19 May 2021 -

Biopharma company GenSight Biologics (Euronext:SIGHT) disclosed on Tuesday the appointments of Laurence Rodriguez, Robert Schupp and Neil Dugdale as the country leads for France, Germany and the UK, respectively, for the commercialisation of LUMEVOQ in H1 2022.

LUMEVOQ, the company's gene therapy for treating Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 mitochondrial gene, is currently under review for marketing authorization in Europe. It expects to achieve UK approval in the same time frame. The anticipated French ATU process allows revenues to be generated from product use while the health technology assessment is still underway.

Most recently, Rodriguez has served as marketing manager, marketing and sales manager and business unit director at Sanofi Genzyme.

Prior to the new role, Schupp was general manager at Santhera, which enabled him to build a strong network among LHON stakeholders, marked by successfully achieving reimbursement for Raxone in Germany.

Previously, Dugdale was employed as the vice president of the Northern Europe sub-region and general manager of the UK and Ireland at Swedish Orphan Biovitrum AB.

Login
Username:

Password: